Abbott Reports Strong Ongoing Third Quarter Results
- Details
- Category: Abbott
Abbott's worldwide sales increased 13.2 percent to $9.8 billion, including a favorable 5.3 percent effect of foreign exchange. Proprietary Pharmaceuticals sales increased 13.5 percent in the quarter.
Bristol-Myers Squibb Announces Changes in Senior Management Team
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) announced a series of related changes within its Senior Management Team. Giovanni Caforio has been promoted to president, U.S. Pharmaceuticals.
Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals
- Details
- Category: Abbott
Today Abbott (NYSE: ABT) announced that it plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals.
Roche reports positive study of Herceptin given by subcutaneous injection
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III HannaH study demonstrated comparable efficacy of a new, investigational subcutaneous (SC) formulation of Herceptin (trastuzumab) to the standard intravenous (IV) infusion of Herceptin in women with HER2-positive early breast cancer.
Novartis drug Gilenya® (fingolimod) has more than 20,000 patient-years of exposure
- Details
- Category: Novartis
Novartis will showcase data from 13 abstracts on fingolimod (Gilenya®), at the 5th Joint Triennial Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) taking place from 19-22 October in Amsterdam.
Bayer HealthCare and Onyx Pharmaceuticals Restructure Global Oncology Partnership
- Details
- Category: Bayer
Bayer HealthCare and Onyx Pharmaceuticals, Inc. restructured their partnership for the global development and marketing of Nexavar® (sorafenib) tablets and entered into a new agreement related to regorafenib, a late-stage oncology compound.
Roche achieves significant progress with personalised healthcare
- Details
- Category: Roche
In the first nine months of 2011 Roche reported positive data from seven clinical studies, several of which have already formed the basis for regulatory filings and approvals in the third quarter:
More Pharma News ...
- Humana and Pfizer Form Research Partnership
- New Study Shows Cialis® Significantly Improved Study Endpoints
- Bristol-Myers Squibb Foundation Announces Collaboration with World Health Organization's Stop TB Department
- AstraZeneca increases investment in China with new $200 million manufacturing facility
- Findings from Two-Year Pivotal Phase III TEMSO Trial
- Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors
- Pfizer Announces Licensing Agreement With Puma Biotechnology